ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations.Applied health economics and health policy · 2022Pooled it
- Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.Hepatology (Baltimore, Md.) · 2020Guideline
- Expanding hepatitis C virus test uptake using self-testing among men who have sex with men in China: two parallel randomized controlled trials.BMC medicine · 2023Trial
- Prevalence and epidemiology of hepatitis C in Uzbekistan: results from a population-based serosurvey, 2022.IJID regions · 2026Article
- Potential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US.Viruses · 2026Article
- Economic evaluations of the primary prevention programs for viral hepatitis-related liver disease and liver cancer: a systematic literature review.Cost effectiveness and resource allocation : C/E · 2026Review
- Association between neighborhood-level overall social vulnerability and cumulative incidence of reported hepatitis C virus infection in Los Angeles County from 2018 to 2023.BMC global and public health · 2026Article
- Cost-Effectiveness of One-Time Universal Childhood Hepatitis C Screening in the United States.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Hepatitis C Screening: A Health Technology Assessment.Ontario health technology assessment series · 2026Article
- Community Versus Facility-Based Services to Improve the Screening of Active Hepatitis C Virus Infection in Cambodia: The ANRS 12384 CAM-C Cluster Randomized Controlled Trial-Protocol for a Mixed Methods Study.JMIR research protocols · 2024Article
- Implementation of Universal Hepatitis C Virus Screening in a Tertiary Cancer Center.Journal of the National Comprehensive Cancer Network : JNCCN · 2024Article
- Annual trends of hepatitis C virus infection in Manitoba between 1998 and 2018: A focus on special populations.Canadian liver journal · 2023Article
- HCV universal EHR prompt successfully increases screening, highlights potential disparities.PloS one · 2023Article
- Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs.American journal of preventive medicine · 2023Article
- A qualitative investigation of the barriers and facilitators to Hepatitis C virus (HCV) screening among individuals experiencing homelessness in Houston, Texas.Dialogues in health · 2022Article
- Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Universal screening for hepatitis C - in for a penny, in for a pound.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Review
- Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy.Journal for immunotherapy of cancer · 2020Review
- Hepatitis C Virus Elimination Requires More Than Good Drugs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: The US Centers for Disease Control and Prevention and the U.S. Preventive Services Task Force recommend one-time hepatitis C virus (HCV) testing for persons born 1945-1965 and targeted testing for high-risk persons. This strategy targets HCV testing to a prevalent population at high risk for HCV morbidity and mortality, but does not include younger populations with high incidence. To address this gap and improve access to HCV testing, age-based strategies should be considered. Methods: We used a simulation of HCV to estimate the effectiveness and cost-effectiveness of HCV testing strategies: 1) standard of care (SOC) - recommendation for one-time testing for all persons born 1945-1965, 2) recommendation for one-time testing for adults ≥40 years (≥40 strategy), 3) ≥30 years (≥30 strategy), and 4) ≥18 years (≥18 strategy). All strategies assumed targeted testing of high-risk persons. Inputs were derived from national databases, observational cohorts and clinical trials. Outcomes included quality-adjusted life expectancy, costs, and cost-effectiveness. Results: Expanded age-based testing strategies increased US population lifetime case identification and cure rates. Greatest increases were observed in the ≥18 strategy. Compared to the SOC, this strategy resulted in an estimated 256,000 additional infected persons identified and 280,000 additional cures at the lowest cost per QALY gained (ICER = $28,000/QALY). Conclusions: In addition to risk-based testing, one-time HCV testing of persons 18 and older appears to be cost-effective, leads to improved clinical outcomes and identifies more persons with HCV than the current birth cohort recommendations. These findings could be considered for future recommendation revisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.